New biomarkers are being evaluated for their ability to advance the management of patients with heart failure. Despite a large pool of interesting candidate biomarkers, besides natriuretic peptides virtually none have succeeded in being applied into the clinical setting. In this review, we examine the best emerging candidates for clinical assessment and management of patients with HF. We provide an update of the 2015 published review in this Journal. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.